The clinical information you need, at your fingertips.

Once-weekly GLP-1 therapy reduced heavy drinking days and alcohol intake in patients with obesity. . .

Oral semaglutide is now available under the Ozempic brand, with new dose strengths and an unchanged clinical profile. . .

A model predicted ten-year risk for 18 obesity-related complications better than body mass index alone, suggesting some overweight patients face risks comparable to those with obesity. . .

Expanded progenitor cell add-on may improve outcomes and broaden donor access in hematologic malignancies. . .

Sibling-controlled analysis suggests familial factors—not medications—drive observed associations. . .

Phase 2 data suggest targeted radiotracer imaging may outperform conventional modalities for early disease. . .

Quit outcomes varied across studies, with consistent e-cigarette use more often linked to success than intermittent use. . .

Methamphetamine use was identified in nearly 15% of acute coronary syndrome cases at one Northern California safety-net hospital, and affected patients had more recurrent events and twice the adjusted risk of death. . .

Agency cites lack of clinical need for semaglutide, tirzepatide, and liraglutide compounding. . .